Genmab A (GMAB) Short-term Investments (2020 - 2025)
Genmab A's (GMAB) quarterly Short-term Investments came in at $140.0 million in Q3 2025, up 225.58% YoY from $43.0 million in Q3 2024, and down 91.27% on a QoQ basis from $1.6 billion in Q2 2025.
Genmab A (GMAB) Short-term Investments (2020 - 2025) Analysis & Trends
Genmab A (GMAB) has 4 years of Short-term Investments data on file, last reported at $140.0 million in Q3 2025.
- Quarterly Short-term Investments rose 225.58% year-over-year to $140.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $140.0 million (up 225.58% YoY) and the FY2025 annual result came in at $80.0 million, down 38.46% from the prior year.
- Short-term Investments declined to $140.0 million in Q3 2025, from $1.6 billion in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $1.6 billion in Q2 2025 to a low of $2.0 million in Q2 2024.
- A 3-year average of $276.1 million and a median of $105.0 million in 2024 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2024 — Short-term Investments sank 94.5% — and 2025, when it soared 80050.0%.
- Tracing GMAB's Short-term Investments over 3 years: stood at $200.0 million in 2023, then slumped by 94.5% to $11.0 million in 2024, then jumped by 1172.73% to $140.0 million in 2025.
- The last three Short-term Investments figures came in at $140.0 million (Q3 2025), $1.6 billion (Q2 2025), and $80.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 140.00 Mn |
| Jun 30, 2025 | 1.60 Bn |
| Mar 31, 2025 | 80.00 Mn |
| Dec 31, 2024 | 11.00 Mn |
| Sep 30, 2024 | 43.00 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 130.00 Mn |
| Dec 31, 2023 | 200.00 Mn |
| Sep 30, 2020 | 2,965.00 |